2020
DOI: 10.1007/s00134-020-06045-y
|View full text |Cite
|
Sign up to set email alerts
|

Machine learning in intensive care medicine: ready for take-off?

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
33
0

Year Published

2020
2020
2022
2022

Publication Types

Select...
6
3

Relationship

1
8

Authors

Journals

citations
Cited by 51 publications
(39 citation statements)
references
References 3 publications
0
33
0
Order By: Relevance
“…We extracted information on the following study characteristics: (1) design (categorized as retrospective-, prospective observational-and clinical [categorized as the following study designs: non-randomized clinical trials and randomized clinical trials/randomized controlled trials (RCT)] designs); (2) aim (categorized as alarm reduction, assessing clinical notes, classifying sub-populations, detecting spurious recorded values, determining physiological thresholds, improving prognostic models/risk scoring system, improving upon previous methods, predicting complications, predicting health improvement, predicting length of stay, predicting medication administration, predicting mortality and predicting readmissions) (in case studies had more than one aim, all aims were recorded); (3) size of the dataset (the total number of patients used for data analysis); (4) level of validation (categorized as internal validation [models are validated on patients who are included in studies' own dataset], external validation [models are validated on data of patients from other geographical locations or times], prospective observational validation, clinical validation and no reported validation); (5) AI level of readiness, which was assessed over time by applying the general concept of technology readiness levels introduced by National Aeronautics and Space Administration (NASA), which previously has been translated to the ICU environment [the consecutive levels increase from development to the clinical implementation of AI: problem identification (level 1), proposal of solution (level 2), model prototyping and development (level 3 and 4), model validation (level 5), real-time testing (level 6), workflow integration (level 7), clinical testing (level 8), and integration in clinical practice (level 9)] [21,22]; (6) clinical study design and effects on patient outcome measures were extracted [categorized as reduced length of ICU stay, reduced overall mortality, reduced time on mechanical ventilation, reduced rate of complications and other (with details)]. Clinical study designs were considered to be either pre-postimplementation trials, non-randomized clinical trials or randomized clinical trials.…”
Section: Data Collection and Review Processmentioning
confidence: 99%
“…We extracted information on the following study characteristics: (1) design (categorized as retrospective-, prospective observational-and clinical [categorized as the following study designs: non-randomized clinical trials and randomized clinical trials/randomized controlled trials (RCT)] designs); (2) aim (categorized as alarm reduction, assessing clinical notes, classifying sub-populations, detecting spurious recorded values, determining physiological thresholds, improving prognostic models/risk scoring system, improving upon previous methods, predicting complications, predicting health improvement, predicting length of stay, predicting medication administration, predicting mortality and predicting readmissions) (in case studies had more than one aim, all aims were recorded); (3) size of the dataset (the total number of patients used for data analysis); (4) level of validation (categorized as internal validation [models are validated on patients who are included in studies' own dataset], external validation [models are validated on data of patients from other geographical locations or times], prospective observational validation, clinical validation and no reported validation); (5) AI level of readiness, which was assessed over time by applying the general concept of technology readiness levels introduced by National Aeronautics and Space Administration (NASA), which previously has been translated to the ICU environment [the consecutive levels increase from development to the clinical implementation of AI: problem identification (level 1), proposal of solution (level 2), model prototyping and development (level 3 and 4), model validation (level 5), real-time testing (level 6), workflow integration (level 7), clinical testing (level 8), and integration in clinical practice (level 9)] [21,22]; (6) clinical study design and effects on patient outcome measures were extracted [categorized as reduced length of ICU stay, reduced overall mortality, reduced time on mechanical ventilation, reduced rate of complications and other (with details)]. Clinical study designs were considered to be either pre-postimplementation trials, non-randomized clinical trials or randomized clinical trials.…”
Section: Data Collection and Review Processmentioning
confidence: 99%
“…To develop the prediction models, we applied five algorithms, including conventional logistic regression, 28 Ridge regression, 29 Elastic net, 30 Kernel‐based Support Vector Machine (SVM), 31 and Random forest, 32 to the derivation dataset. The hyperparameters and model architecture for these algorithms were selected using a 10‐fold cross‐validation (CV) to prevent overfitting and to eliminate data bias in model selection.…”
Section: Methodsmentioning
confidence: 99%
“…In a recent review of 172 AI-driven solutions created from routinely collected chart data, the clinical readiness level for AI was low. In that study, the maturity of the AI was classified into nine stages corresponding to real world application [ 33 ]. Strikingly, around 93% of all analyzed articles remained below stage 4, with no external validation process, and only 2% of published studies had performed prospective validation.…”
Section: Pitfalls Of Ai In Critical Carementioning
confidence: 99%